Sam Brusco, Associate Editor06.13.22
Onkos Surgical has entered an agreement to purchase Stryker’s Juvenile Tumor System (JTS), which enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, and severe trauma, revisions, oncology, and malignant diseases.
The JTS helps non-invasively lengthen the implant post-surgery in a clinical setting. It removes the need for multiple lengthening surgeries, anesthesia, or sedation to reduce complication risk and limb reconstruction surgery costs.
"This is a significant day for Onkos Surgical and the musculoskeletal oncology community," Patrick Treacy, Onkos Surgical co-founder and CEO told the press. "Our 'Why' has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission. We are committed to being good stewards of the technology. We are proud to collaborate with this dedicated surgeon community and excited to create a bright future for the technology as we continue this meaningful work for pediatric musculoskeletal cancer patients."
The JTS helps non-invasively lengthen the implant post-surgery in a clinical setting. It removes the need for multiple lengthening surgeries, anesthesia, or sedation to reduce complication risk and limb reconstruction surgery costs.
"This is a significant day for Onkos Surgical and the musculoskeletal oncology community," Patrick Treacy, Onkos Surgical co-founder and CEO told the press. "Our 'Why' has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission. We are committed to being good stewards of the technology. We are proud to collaborate with this dedicated surgeon community and excited to create a bright future for the technology as we continue this meaningful work for pediatric musculoskeletal cancer patients."